^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA® MET (SP44) RxDx Assay

    Company:
    Roche
    Type:
    FDA Approved (PMA)
    Related tests:
    Details
    Evidence

    News

    29d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv) • simmitinib (SYHA1817)